Stephen Meng, MD
Cardiovascular Disease · Newark, DENPI 1083974257
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Amgen accounts for 65.0% of it on its own, with 31 other manufacturers making up the rest.
Across 351 payments — averaging $48.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$725
- Pfizer$569
- Boehringer Ingelheim$523
- Regeneron Healthcare Solutions, Inc.$496
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$9,54456%
- Food & beverage$7,33343%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $11,005 |
| Novartis | 77 | $1,159 |
| E.r. Squibb & Sons, L.L.C. | 31 | $725 |
| Pfizer | 29 | $569 |
| Boehringer Ingelheim | 32 | $523 |
| Regeneron Healthcare Solutions, Inc. | 22 | $496 |
| AstraZeneca | 24 | $430 |
| Heartflow, Inc. | 7 | $252 |
| Johnson & Johnson | 17 | $238 |
| Esperion Therapeutics, Inc. | 10 | $212 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $132 |
| Kaneka Medical America LLC | 1 | $124 |
| W. L. Gore & Associates, Inc. | 2 | $119 |
| Abiomed | 1 | $107 |
| Kestra Medical Technology Services, Inc. | 4 | $99 |
| Okami Medical, Inc. | 1 | $94 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Medtronic | 1 | $72 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $62 |
| Boston Scientific | 3 | $59 |
| Sanofi | 2 | $56 |
| Ionis Pharmaceuticals, Inc. | 3 | $54 |
| Bayer | 2 | $45 |
| Chiesi USA, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Merck | 2 | $32 |
| Preventice Services, LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Terumo Medical Corporation | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,938 in reported general payments places this provider in the 85th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $235,058 |
| Repatha SureclickEvolocumab | 101 | $133,182 |
| XareltoRivaroxaban | 78 | $106,083 |
| JardianceEmpagliflozin | 22 | $34,792 |
| EntrestoSacubitril/Valsartan | 15 | $29,014 |
| Praluent PenAlirocumab | 20 | $23,163 |
| BrilintaTicagrelor | 14 | $16,296 |
| VascepaIcosapent Ethyl | 18 | $11,511 |
| Ezetimibe | 213 | $9,145 |
| Atorvastatin Calcium | 507 | $6,759 |
| Metoprolol Succinate | 303 | $4,998 |
| Rosuvastatin Calcium | 207 | $3,965 |
| Amlodipine Besylate | 251 | $1,805 |
| Carvedilol | 181 | $1,708 |
| Losartan Potassium | 158 | $1,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $569 | $235,058151 claims |
| Johnson & JohnsonXarelto | $238 | $106,08378 claims |
| Boehringer IngelheimJardiance | $523 | $34,79222 claims |
| NovartisEntresto | $1,159 | $29,01415 claims |
| AstraZenecaBrilinta | $430 | $16,29614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Francis PalermoNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.